ARO ENaC
Alternative Names: ARO-ENaC; ARO-Lung1Latest Information Update: 01 Mar 2022
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antifibrotics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cystic fibrosis
Most Recent Events
- 08 Feb 2022 Arrowhead Pharmaceuticals terminates the phase I/II AROENaC1001 trial for Cystic fibrosis in Australia and New Zealand due to business decisions (NCT04375514)
- 02 Jul 2021 Arrowhead Pharmaceuticals temporarily pauses Phase-I/II clinical trials in Cystic fibrosis in Australia and New Zealand pending toxicology analysis (Inhalation) (NCT04375514)
- 24 Feb 2021 Phase-I/II clinical trials in Cystic fibrosis in Australia (Inhalation) before February 2021 (NCT04375514)